PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-9.94%
Negative yoy D&A while RVPH is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-368.86%
Negative yoy deferred tax while RVPH stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
368.86%
SBC growth while RVPH is negative at -56.99%. John Neff would see competitor possibly controlling share issuance more tightly.
55.40%
Less working capital growth vs. RVPH's 125.07%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
AP growth well above RVPH's 101.70%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-12.95%
Negative yoy usage while RVPH is 159.63%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
200.11%
Well above RVPH's 81.82%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-85.28%
Negative yoy CFO while RVPH is 38.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
80.16%
CapEx growth of 80.16% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
We expand invests by 80.16% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
54.75%
Debt repayment similar to RVPH's 52.51%. Walter Schloss sees parallel liability management or similar free cash flow availability.
-0.41%
Negative yoy issuance while RVPH is 4129.39%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.